Bringing minimal residual disease (MRD) measurement to the clinic
MRD measurement: next-generation sequencing or flow cytometry?
Progession of AML treatment over the past decades
The utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele
What is the future of treating ALL?